Rinvoq® (upadacitinib) – New indication
May 18, 2023 - The FDA announced the approval of AbbVie’s Rinvoq (upadacitinib), for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
Top